Introduction
The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol guideline was recently published. 1 The overwhelming number of clinical practitioners who deliver the majority of cardiovascular (CV) care will not study this extensive document in any detail. Keeping it simple seems essential to provide a practical and clinically useful guidance for medical providers who care for the majority of patients where ''the rubber meets the road.'' It is good to provide extensive information for the highly specialized clinical or basic science investigator, but easily understood, evidencebased, and practical applied principles are essential when trying to reach overworked clinical caregivers. It is highly unlikely that, faced with a very full waiting room, many clinicians go to a computer to assess a risk equation.
No specific low-density lipoprotein cholesterol (LDL-C) level has been proven as established, despite the 70 mg/dL (1.8 mmol/L) recommended for diabetic and other high-risk patients in 2004. 2 Despite 70 mg/dL (1.8 mmol/L) as a convenient target, and its acceptance by many practitioners, there was some recent controversy that targets should be abandoned in favor or tailoring. [3] [4] [5] Some combination of both options appears appropriate since a patient with an LDL-C well below 100 mg/dL (2.6 mmol/L) with an acute CV event has other factors involved. An appropriate approach may also include LDL-C lowering below the levels considered therapeutic by most clinicians. In support of this, there is evidence, as in the case of patients with acute coronary syndrome (ACS), who have been shown to do better with an LDL-C of <40 mg/dL (1.0 mmol/L) or in the 40 to 60 mg/dL (1.0-1.5 mmol/L) range. 6 The purpose of this editorial is to assess and contribute to simplification of the 2013 guideline. 1
National Cholesterol Education Program Adult Treatment Panel III
The updated clinical guidelines of the National Cholesterol Education Program (NCEP) that appeared in 2001 were presented as the Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 7 This was abbreviated as Adult Treatment Panel (ATP) III. The Expert Panel assessed the new aspects of their recommendations as follows: diabetes mellitus (DM) was to be considered a coronary heart disease (CHD) risk equivalent 7 ;
Framingham Heart Study risk projections of 10-year CHD risk were to be used 8 ; individuals with metabolic syndrome were advised to make significant lifestyle changes 7 ; a desirable level for LDL-C was considered to be <100 mg/dL (2.6 mmol/L); a low level of high-density lipoprotein cholesterol (HDL-C) was changed from <35 mg/dL (0.9 mmol/L) to <40 mg/dL (1.0 mmol/L); and increased attention was given to moderate triglyceride elevations.
Current State of Primary Care Practice in Lipid Management
An unfortunate reality is that, despite the previous ATP III guidelines 7 and the new ACC/AHA guideline, 1 of 65 million considered eligible for lipid modification in 2003, Bottorff found that <45% were receiving lipid-lowering therapy. 9 In addition, >75% of patients given lipid-lowering therapy did not attain the ATP III goal and <30% of patients started on appropriate treatment continued that therapy past 1 year. 9 The Lipid Treatment Assessment Project (L-TAP) study in 2000 found that only 37% of high-CV risk patients achieved their NCEP goals at that time, 10 which was just before the ATP-III era. In 1999, Cabana et al selected 76 published studies from a search of 5658 articles that described at least 1 barrier affecting adherence to guidelines. 11 The potential reasons were lack of awareness, lack of familiarity, lack of agreement, lack of outcome expectancy, and failure to resolve the inertia of previous practice habits. 11 In another study of responses obtained from 888 primary care physician practitioners in 2008, Doroodchi et al found that guideline adherence had an inverse relationship both to years of practicing medicine and to number of patients seen. 12 These authors cited as significant barriers to CV disease risk management, medication cost (87.7%), medication adherence (74.1%), lack of sufficient counseling time (55.7%), lack of patient education tools (47.1%), and insufficient dietary knowledge and skills for effecting alterations in diet (47.8%). 12 It appears that there are several reasons for the failure of primary care practitioners to follow CV disease guidelines during various eras. One additional consideration is that changing and complicating recommendations, especially without major indications and solid proof, may add to confusion as well as resistance to following guidelines.
Low-Density Lipoprotein Cholesterol Targets
What the desired LDL-C target should be for the high-CV risk patient remains unresolved. Nevertheless, there is continued commentary on LDL-C targets 13, 14 and ample evidence that lower is better. 15 The Greek Atorvastatin and Coronary-heartdisease Evaluation study (GREACE) involved usual care versus targeted to LDL-C goal 100 mg/dL (2.6 mmol/L). A mean atorvastatin dose of 24 mg/d resulted in a 46% reduction in LDL-C, associated with a CHD event risk ratio of 0.49 (confidence interval [CI] 0.27-0.73; P < .0001). 16 In the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE-IT-TIMI 22) study, significantly fewer CV events occurred in the LDL-C <40 mg/dL (1.0 mmol/L) and LDL-C >40 to 60 mg/dL (1.0-1.5 mmol/L) groups, compared with the median LDL-C 62 mg/dL group (1.6 mmol/L). 17 There was a similar beneficial result for the lowest LDL-C <50 mg/L (1.3 mmol/L) group of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study. A meta-analysis involving 38 153 patients on statin therapy found that those patients in the group achieving the lowest LDL-C <50 mg/dL (1.3 mmol/L) had the lowest hazard ratio for major CV events: 0.44 (95% CI 0.35-0.55). 18 Also, an assessment of a hypobetaliproteinemia kindred where the average LDL-C was 31 mg/dL (0.8 mmol/L) 19 concluded that essentially they have no CV disease. 20 Nevertheless, such studies still do not define a specific LDL-C target.
Despite the absence of specific agreed-upon evidence for an LDL-C target and the evidence for widespread failure by primary care physicians to treat a majority of high-CV risk patients appropriately, further confusion has been added by the assertion that a tailored approach to LDL-C and CV risk management is indicated, instead of a specific number target. In a published ''open letter'' in 2012, Hayward and Krumholz commented on their opinion that there was no scientific basis for treating an LDL-C target and went on to state that a tailored treatment is simpler, safer, more effective, and has a better evidence basis. 3 However, is such a quantum change justified when there are, as documented, still many problems getting practitioners to recommend/implement aggressive CV risk modification? 4 The LDL-C has been a simple and convenient target for CV risk modification, but, of course, realization that no specific target or cutoff LDL-C level has been established is essential. 21 Nevertheless, there is ample evidence that lower appears to be better, as in a study of 6107 patients with LDL-C <60 mg/dL (1.5 mmol/L), where the addition of a statin resulted in improved survival. 22 Therefore, tailoring comes into play depending on initial LDL-C levels. One conclusion is that <70 mg/dL (1.8 mmol/L) is better, and the presence of other CV risk factors such as tobacco abuse, DM, and hypertension add further emphasis to the importance of LDL-C lowering, although this has frequently been difficult to achieve. 23 
Summary of the ACC/AHA 2013 Cholesterol Guideline
With the 2013 guideline, we are faced with an extensive document to digest. 1 An attempt to summarize the 2013 blood cholesterol guideline centers around 4 statin benefit groups ( Table 1) , which include clinical CV disease, LDL-C 190 mg/dL (4.9 mmol/L), patient with DM aged 40 to 75 years with no clinical CV disease plus LDL-C 70 to 189 mg/dL (1.8-4.9 mmol/L), and no clinical CV disease or DM, LDL-C 70 to 189 mg/dL (1.8-4.9 mmol/L), and estimated 10-year CV risk 7.5%. The stated guideline goal is ''significant'' LDL-C reduction or 50% from the untreated baseline without a specific LDL-C target to be achieved by a high-dose statin. 1 To estimate the 10-year CV risk, there are pooled cohort equations available online that accept specific patient data. 24 Future guideline updates will become available. 1 It is relevant to consider that, based on CV risk assessment and starting LDL-C levels, the clinician will still likely choose to pick out an individualized target LDL-C level to attain, due to ample evidence that lower is better and associated with less CV disease. 2, 17, 25 New-onset CV disease in a patient with a low initial LDL-C not far from 70 mg/dL (1.8 mmol/L) suggests aiming for a LDL-C target significantly <70 mg/dL (1.8 mmol/L). Another problem not addressed is that associated with the continued use of high-dose statins. During the likely Goal is to use high-dose statin to attain a ''significant'' LDL-C reduction of 50% from the untreated baseline without specifying a specific LDL-C target Estimation of 10-year CV risk can be made by cohort equations available on the Internet period of inflammation associated with an acute CHD event, clinical evidence backs the use of high-dose atorvastatin 80 mg/d. 6, 26 However, following the likely resolution of acute inflammation in a period of 3 months, a high-dose statin has more associated problems with myopathy. In addition, the true incidence of myopathy in association with a statin is 10.5%, 27 not the much lower level of approximately 1% to 5% as reported by pharmaceutical companies. 28 An explanation of this discrepancy is run-in phases where all participants take the statin to be studied and then anyone with a problem is eliminated before the randomization phase. 29 Concern has been raised regarding possible conflicts of interest involving some panelists who wrote the ACC/AHA 2013 guideline. 1 The British Medical Journal published a concern about possible conflicts of interest. 30 Although this could not be independently verified by the author of this editorial, even the perception of any panelists having conflicts of interest before or during their participation is a concern. 30 Commentary regarding such a published concern of possible conflict is appropriate, since it can be contended that there are numerous qualified physicians and scientists who are completely free of industry conflicts and desirous of participation on such a panel. Unfortunately, the ACC has only specified that at least 50% of writing committees should have no inappropriate relationship with industry. 31 A fair question to ask is why should the standard for any ACC, AHA, or other organizational guideline panel not be to have all panelists conflict free, especially if there is an ample pool of conflict-free candidates for such panels? Unfortunately, part of the answer may lie in the fact that there is insufficient financial support available from governments and professional organizations to support clinical investigation and scholarly pursuits. Therefore, various links to industry may appear unavoidable to some investigators.
Other Cholesterol Guidelines
The failure of other interested medical specialty organizations to universally accept the ACC/AHA 2013 guideline puts an emphasis on the problematic nature of the new guideline. The Expert Dyslipidemia Panel of the International Atherosclerosis Society in 2014 recommended the optimal LDL-C for primary CV disease prevention as <100 mg/dL (2.6 mmol/L) and for secondary CV disease prevention, their recommendation was LDL-C <70 mg/dL (1.8 mmol/L). 32 In addition, it has been reported that the American Association of Clinical Endocrinologists and the National Lipid Association (NLA) have taken exception to removal of LDL-C goals by the ACC/AHA 2013 guideline. 33 The NLA actually prefers the use of non-HDL-C over LDL-C. 34, 35 In addition, the European Society of Cardiology and the European Atherosclerosis Society (ESC/EAS) in 2011 published a treatment target for patients with very high CV risk as LDL-C <70 mg/dL (1.8 mmol/L), or a 50% decrease in the baseline LDL-C of high-CV risk patients. 36 In 2013, the ESC/EAS commented on the focus of the ACC/AHA guideline on high-intensity statin therapy compared with the ESC/EAS guidelines. The ESC/EAS considered that their guidelines offered an approach with greater breadth regarding dyslipidemia in general as well as consideration of drug treatment options other than statins. 37 
Statins Versus Other Approaches for Maximum LDL-C Lowering
Maximum LDL-C lowering can be enhanced by the addition of other medication to a statin when a desired LDL-C level is not achieved. The major outcome studies assessed percentage of LDL-C reduction with reduction in LDL-C as a goal. [38] [39] [40] [41] A level of LDL-C <70 mg/dL (1.8 mmol/L) has simply been suggested as an appropriate goal for the high-CV risk patient, 2, 36 which appears modifiable by the baseline LDL-C. Multiple studies with different approaches to decrease LDL-C over and above using a statin (including some before the statin era), such as cholestyramine resin, 42, 43 improvement in quantitative coronary angiography with colestipol and nicotinic acid, 44, 45 ileal bypass, 46, 47 and LDL-C apheresis, 48, 49 all confirm that the lower the LDL-C, the more favorable the CV risk modification. As a further confirmation, it has been problematic to show benefit from LDL-C reduction in kidney disease, and yet, the Study of Heart and Renal Protection (SHARP) trial with simvastatin and ezetimibe resulted in a decreased occurrence of major CV events in patients with advanced renal disease (on and not on dialysis). 50 In addition, the lower than average risk of CV disease in the presence of congenital hypobetalipoproteinemia 51 adds further support for a low LDL-C even without a statin. Therefore, there is outcomes-based evidence to support LDL-C reduction alone and in the absence of a statin.
Conclusions
The new 2013 ACC/AHA guideline has to be understood and dealt with. Unfortunately, it is long, tedious, complicated, and fails to give the clinical practitioner easy-to-use and specific guidance. In addition, the possible conflicted status of several members of the panel raises some concern. An attempt to simplify the guideline is made in Table 1 . As described, acceptance of the guideline is far from universal. There is much of value in previous and other guidelines. Unfortunately, the provider, as he or she is now called in the United States, has to synthesize the many recommendations available and come to a decision. However, it appears appropriate to state that there is good evidenced-based data supporting initial high-dose statin use in ACS and then continued statin use in association with other medications and approaches. The latter is directed at attainment of a major LDL-C reduction in the patient with significantly elevated CV risk.
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